Recent industry reports have highlighted past and projected rapid expansion in the DNA diagnostics and genomics markets, driven by liquid biopsies, direct-to-consumer testing, and personalized ...

Most biopharma players need access to gene sequencing services. Illumina is facing a handful of headwinds, but it's still the market leader. Bionano Genomics is unproven but expanding quickly. So ...

Longstanding partners bring together end-to-end workflows and leading CRISPRPerturb-seq technologies setting a standard for single-cell studies and enabling a 5billion single-cell atlas ecosystem ...

The move by the commission is seen as a test of regulators’ efforts to prevent big companies from buying small innovators. By Steve Lohr Steve Lohr first wrote about Illumina’s confrontation with the ...

Illumina’s announced partnerships with IBM’s Watson and Philips help shore up the firm's data-analysis capabilities and clinical diagnostic marketing efforts, respectively, but the announcement of a ...

Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its first product based on its novel Illumina Complete Long Read technology is now ...

Illumina, Commercial Metals and Newmont stand out as brokers boost ratings amid inflation concerns and shifting economic signals.

"Illumina has set the standard in whole genome sequencing, and now, with Broad's deep experience and long history of translating complex molecular biology assays into high-throughput, high quality ...

It happens in Hollywood and on Broadway: Sometimes a great production wins mostly positive reviews from the critics but fails to wow the audience. The critics here are analysts, who largely applauded ...

SAN FRANCISCO—Illumina said Monday it will join with Nashville Biosciences and Amgen’s deCODE Genetics subsidiary on a collaboration to whole-genome sequence the largest-ever dataset of genomes from ...